Psoriasis and Cardiomyopathy: A Review of the Literature Psoriasis and Cardiomyopathy: A Review of the Literature

The incidence of dilated cardiomyopathy is 10 times higher in patients with psoriasis than in the general population. What might be the possible etiology of this association?Southern Medical Journal
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news

Related Links:

AbbVie Inc. said it's buying Dublin, Ireland-based drug firm Allergan in a $63 billion deal. AbbVie (NYSE: ABBV), based in North Chicago, Illinois, said it's paying 0.8660 of its shares and $120.30 in cash for each Allergan (NYSE: AGN) share, for a total consideration of $188.24 per Allergan share. AbbVie said the combined companies' headquarters will remain in North Chicago. "This is a transformational transaction for both companies and achieves unique and complementary strategic objectives.…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Publication date: September 2019Source: Phytochemistry, Volume 165Author(s): Takahiro Okada, Hideyuki Ihara, Yoshitaka IkedaAbstractIn higher plants, asparagine-linked oligosaccharides (N-glycans) in glycoproteins carry unique carbohydrate epitopes, namely, a core α1,3-fucose and/or a β1,2-xylose, which are common determinants responsible for the cross-reactivity of plant glycoproteins due to their strong immunogenicity. While these determinants and the relevant genes have been well characterized for herbaceous plants, information concerning whether many food plants cross-react with airborne pollens is not avail...
Source: Phytochemistry - Category: Chemistry Source Type: research
Condition:   Transthyretin Amyloidosis (ATTR) With Cardiomyopathy Interventions:   Drug: Placebo;   Drug: Patisiran Sponsor:   Alnylam Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Pneumonia, Bacterial;   Viral Infection;   Clinical Pneumonia;   Plasmodium Falciparum Malaria;   Malaria;   Infections, Respiratory Intervention:   Sponsors:   Boston University;   National Institute of Allergy and Infectious Diseases (NIAID);   Medical Research Council Unit, The Gambia, LSTMH;   Laboratory of Transnational Immunology, UMC Utrecht Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Moderate-to-severe Chronic Plaque Psoriasis Interventions:   Drug: Tildrakizumab;   Drug: Placebo - tildrakizumab;   Drug: Etanercept Sponsor:   Sun Pharma Global FZE Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Latest drug industry megamerger comes as AbbVie faces patent expiration for Humira
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
The acquisition aims to diversify AbbVie beyond its top-selling drug Humira, which will soon lose patent protection
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news
Authors: Gearry RB, Frampton C, Inns S, Poppelwell D, Rademaker M, Suppiah R Abstract Objective: VITALITY, a 6-month, multicenter, prospective, observational study, assessed the effects of originator adalimumab (HUMIRA®) on health and disability outcomes in patients with Crohn's disease (CD), rheumatoid arthritis (RA), or psoriasis treated in routine clinical practice in New Zealand (NZ). Methods: Biologic-naïve adults initiating adalimumab in accordance with NZ funding requirements were recruited. Primary endpoint was 6-month change from baseline in World Health Organization Disability Assessment Schedule...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
AbbVie Inc. said it's buying Dublin, Ireland-based drug firm Allergan in a $63 billion deal. AbbVie (NYSE: ABBV), based in North Chicago, Illinois, said it's paying 0.8660 of its shares and $120.30 in cash for each Allergan (NYSE: AGN) share, for a total consideration of $188.24 per Allergan share. AbbVie said the combined companies' headquarters will remain in North Chicago. "This is a transformational transaction for both companies and achieves unique and complementary strategic objectives.…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
AbbVie Inc. said it's buying Dublin, Ireland-based drug firm Allergan in a $63 billion deal. AbbVie (NYSE: ABBV), based in North Chicago, Illinois, said it's paying 0.8660 of its shares and $120.30 in cash for each Allergan (NYSE: AGN) share, for a total consideration of $188.24 per Allergan share. AbbVie said the combined companies' headquarters will remain in North Chicago. "This is a transformational transaction for both companies and achieves unique and complementary strategic objectives.…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
More News: Allergy | Allergy & Immunology | Cardiology | Cardiomyopathy | Dermatology | Dilated Cardiomyopathy | Heart | Psoriasis | Skin